GLP-1 RAs may be linked with reduced risk for atrial arrhythmias (RR: 0.81; 95% CI: 0.70–0.95).; GLP-1 RAs appear to have a stronger anti-atrial arrhythmia impact in patients with T2DM and MI. This evidence concerns the gene GLP1R and myocardial infarction.